Harbour BioMed has entered into a strategic collaboration with China National Pharmaceutical Group Co., Ltd. (Sinopharm) to establish the Sinopharm – Harbour BioMed Innovation Consortium, aimed at accelerating the research and development of innovative biologics.
The companies will collaborate across the entire biologics development process, with a focus on oncology, immune-mediated inflammatory diseases and other therapeutic areas.
Under the agreement, Harbour BioMed will contribute its Harbour Mice fully human antibody technology platform and AI-enabled drug discovery capabilities to discover and optimize antibody candidates. Sinopharm will oversee clinical development, commercial-scale manufacturing and commercialization of therapies developed through the partnership.
The companies will jointly fund research and development activities and share product rights under mutually agreed terms.
“This partnership with Sinopharm represents another important step in advancing our ‘platform + pipeline’ strategy in China,” said Dr. Jingsong Wang, founder, chairman and CEO of Harbour BioMed.
Harbour BioMed has previously established strategic collaborations with global pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb, and Pfizer.
“The establishment of an innovation R&D consortium with Harbour BioMed represents a key move by Sinopharm to optimize resource allocation and enhance R&D efficiency,” Sinopharm said.
